Sign In
Buy JNJ
$241.00
+1.92 (+0.80%)
At Close: Jun 24, 2026
Johnson & Johnson Q2: Robust New Product Pipeline
03:06pm, Wednesday, 17'th Jul 2024
Johnson & Johnson beats market estimates for revenue and EPS in Q2 FY24. A strong product pipeline includes new drugs for ulcerative colitis and lung cancer. JNJ's acquisition of Shockwave Medical pos
Johnson & Johnson CFO talks Q2 earnings, medtech business
02:51pm, Wednesday, 17'th Jul 2024
Johnson & Johnson (JNJ) reported second-quarter earnings that beat estimates on both revenue and profit. The company posted revenue of $22.45 billion, surpassing the expected $22.34 billion, while adj
5 Deep Value Stocks To Buy in July
01:04pm, Wednesday, 17'th Jul 2024
Warren Buffett champions value investing, focusing on undervalued companies with strong fundamentals for long-term growth and stability.
J&J (JNJ) Q2 Earnings & Sales Top, EPS View Cut on M&A Costs
12:30pm, Wednesday, 17'th Jul 2024
J&J (JNJ) beats estimates for second-quarter earnings and sales. It lowers earnings expectations for 2024 due to costs related to recent acquisitions.
Housing Starts Increased More Than Expected
12:21pm, Wednesday, 17'th Jul 2024
Pre-market futures are down this morning. This does not appear to be as a result of any releases ahead of the open, but as sort of a mass realization that markets have climbed historically high over t
Johnson & Johnson (JNJ) Q2 2024 Earnings Call Transcript
12:17pm, Wednesday, 17'th Jul 2024
Johnson & Johnson (NYSE:JNJ ) Q2 2024 Earnings Conference Call July 17, 2024 8:30 AM ET Company Participants Jessica Moore - Vice President, Investor Relations Joe Wolk - Executive Vice President, Chi
Johnson & Johnson climbs after earnings and revenue beat
11:44am, Wednesday, 17'th Jul 2024
Johnson & Johnson (NYSE:JNJ) shares climbed 3% after second-quarter earnings fell less than expected. Helped by 8% sales from its pharmaceutical arm, group revenue rose 4.3% to $22.45 billion, whi
This Medical Giant's Stock Rebounds: A 15% Upside Is the Minimum
10:52am, Wednesday, 17'th Jul 2024
Johnson & Johnson NYSE: JNJ has struggled for the last year or two as the impacts of COVID-19 and the spin-off of Kenvue NYSE: KVUE work their way through the system. The takeaway from the Q2 earnings
Johnson & Johnson CFO on drug pricing
10:38am, Wednesday, 17'th Jul 2024
Johnson & Johnson executive vice president and CFO Joseph Wolk discusses high drug prices and breaks down the company's growth outlook.
Johnson & Johnson (JNJ) Reports Q2 Earnings: What Key Metrics Have to Say
10:31am, Wednesday, 17'th Jul 2024
While the top- and bottom-line numbers for Johnson & Johnson (JNJ) give a sense of how the business performed in the quarter ended June 2024, it could be worth looking at how some of its key metrics c
Johnson & Johnson Posts Mixed Earnings, Shifts Full-Year Guidance
09:46am, Wednesday, 17'th Jul 2024
Johnson & Johnson (JNJ) reported mixed second-quarter results Wednesday, as one-time costs caused the company to miss profit estimates despite better-than-expected sales.
Johnson & Johnson (JNJ) Beats Q2 Earnings and Revenue Estimates
08:30am, Wednesday, 17'th Jul 2024
Johnson & Johnson (JNJ) came out with quarterly earnings of $2.82 per share, beating the Zacks Consensus Estimate of $2.71 per share. This compares to earnings of $2.80 per share a year ago.
Johnson & Johnson's Q2 Earnings: Revenue And Profit Beat On Strong Pharma Sales, Annual Profit Outlook Lowered On M&A Costs
08:14am, Wednesday, 17'th Jul 2024
On Wednesday, Johnson & Johnson JNJ reported a second-quarter adjusted EPS of $2.82, up 10.2% year-over-year, beating the consensus of $2.70.
J&J CFO Joseph Wolk on Q2 earnings beat: Very pleased with the performance overall
08:03am, Wednesday, 17'th Jul 2024
Johnson & Johnson executive vice president and CFO Joseph Wolk joins 'Squawk Box' to break down the company's quarterly earnings results, growth outlook, and more.
Johnson & Johnson beats on top and bottom lines in Q2
07:54am, Wednesday, 17'th Jul 2024
CNBC's Becky Quick reports on the company's quarterly earnings results.
